{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["enfortumab vedotin","pembrolizumab"]],"indication":"locally advanced or metastatic urothelial carcinoma","name":"CAST-AI","nct_id":"NCT06764095","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cast-ai-nct06764095. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive standard of care enfortumab vedotin IV over 30 minutes on day 1 and day 8 and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for at least 4 cycles (12 weeks) in the absence of disease progression or unacceptable toxicity. Patients who are surgical candidates may then undergo cytoreductive cystectomy and/or ureterectomy. Patients may also undergo MDT at any time per standard of care. After surgery, patients may then continue to receive maintenance enfortumab vedotin and pembrolizumab. Additionally, patients undergo urine and blood sample collection, CT, PET/CT or MRI throughout the study.","label":"Treatment (enfortumab vedotin, pembrolizumab)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2032-01-01","type":"ESTIMATED"},"conditions":["Locally Advanced Bladder Urothelial Carcinoma","Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma","Metastatic Bladder Urothelial Carcinoma","Metastatic Renal Pelvis and Ureter Urothelial Carcinoma","Stage III Bladder Cancer AJCC v8","Stage IV Bladder Cancer AJCC v8","Stage IV Renal Pelvis and Ureter Cancer AJCC v8"],"enrollment":{"count":75,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","tomography"],"type":"PROCEDURE"},{"name":"Cystectomy","otherNames":[],"type":"PROCEDURE"},{"name":"Enfortumab Vedotin","otherNames":["AGS 22ME","AGS-22M6E","Anti-Nectin 4 ADC ASG-22CE","Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E","ASG 22CE","ASG-22CE","ASG22CE","Enfortumab Vedotin-ejfv","Padcev"],"type":"DRUG"},{"name":"Local Therapy","otherNames":["Localized Therapy"],"type":"PROCEDURE"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Pembrolizumab","otherNames":["BCD-201","GME 751","GME751","Keytruda","Lambrolizumab","MK 3475","MK-3475","MK3475","Pembrolizumab Biosimilar BCD-201","Pembrolizumab Biosimilar GME751","Pembrolizumab Biosimilar QL2107","Pembrolizumab Biosimilar RPH-075","QL2107","RPH 075","RPH-075","RPH075","SCH 900475","SCH-900475","SCH900475"],"type":"BIOLOGICAL"},{"name":"Positron Emission Tomography","otherNames":["Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron emission tomography (procedure)","Positron Emission Tomography Scan","Positron-Emission Tomography","proton magnetic resonance spectroscopic imaging","PT"],"type":"PROCEDURE"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"},{"name":"Ureterectomy","otherNames":[],"type":"PROCEDURE"}],"last_update":"2026-10-01","lead_sponsor":"Mayo Clinic","official_title":"CAST-AI: Cystectomy After Systemic Therapy With ADC and Immunotherapy","overall_status":"RECRUITING","phases":["PHASE4"],"primary_completion_date":{"date":"2028-07-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) at 12 months","timeFrame":"At 12 months"}],"references":[],"start_date":{"date":"2025-01-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial","url":"https://clinicaltrials.gov/study/NCT06764095"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cast-ai-nct06764095"}